Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in patients with advanced…

Overview of attention for article published in Journal for Immunotherapy of Cancer, January 2023

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (71st percentile)
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 3 X users

wikipedia: 1 Wikipedia page

Readers on

mendeley: 38 Mendeley

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 12,778 followers.

RT @jitcancer: New #JITC article: Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of i…

New #JITC article: Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), w/ or w/o pembrolizumab, in patients with advanced solid tumors https://t.co/HIxfs9o3nA @ch…

New 3i Investigator Article Alert!! Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in patients with advanced solid tumors htt…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity.